Abstract:BackgroundAbnormal expression of microRNAs (miRNAs) is related to human carcinogenesis. Although previous studies have shown that miR-503 expression in gastric cancer (GC) is downregulated, however, the underlying molecular mechanism for miR-503 involved in gastric cancer development is still largely unknown.MethodsThe relative expression of miR-503 in GC tissues and adjacent normal tissues was examined using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analyses. In vitro, cell proliferation and invasion were evaluated by using CCK8, cell colony and transwell invasion assays. In vivo, xenograft tumor model was constructed to assess miR-503 expression whether affects tumor growth or not. Luciferase reporter assay, qRT-PCR and western blot assay were used to demonstrate HMGA2 is a target of miR-503.ResultsWe demonstrated that miR-503 expression was significantly downregulated in GC tissues and cell lines compared to adjacent normal tissues and normal gastric mucosa cell lines, respectively. Lower miR-503 expression associated with tumor size, lymph node metastasis, and predicted a poor overall survival (OS) time in GC patients. Subsequently, in vitro, gain-function and loss-function assays confirmed that miR-503 overexpression significantly suppressed GC cell proliferation, colony formation and cell invasion, while decreased miR-503 expression had an adverse effect in GC cells. Furthermore, we found that miR-503 specifically targeted the 3′-UTR regions of HMGA2 mRNA and suppressed its protein expression. Overexpression of HMGA2 could reverse the miR-503 mediated inhibition of GC cell proliferation and invasion. In vivo, miR-503 overexpression dramatically reduced tumor growth. Moreover, we demonstrated that miR-503 suppressed WNT/β-catenin signaling by elevating GSK-3β and p-β-catenin expression, but decreased p-GSK-3β and β-catenin expression in GC cells.ConclusionThese results provide that miR-503 expression acts as a predictor for GC prognosis and may have a potential application in GC therapy.

MiR-140-3p Impedes Gastric Cancer Progression and Metastasis by Regulating BCL2/BECN1-Mediated Autophagy

Retracted: Mir‐944 Inhibits Metastasis of Gastric Cancer by Preventing the Epithelial–mesenchymal Transition Via MACC1/Met/AKT Signaling

Mir-140-3p is Involved in the Occurrence and Metastasis of Gastric Cancer by Regulating the Stability of FAM83B

MiR-1-3p Targets CENPF to Repress Tumor-Relevant Functions of Gastric Cancer Cells

MiR-301a-5p/SCIN promotes gastric cancer progression via regulating STAT3 and NF-κB signaling

Mir-338-3p Functions As a Tumor Suppressor in Gastric Cancer by Targeting PTP1B

Mir-301a-5p/Scin Promotes Gastric Cancer Progression Via Regulating Stat3 And Nf-Kappa B Signaling

miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2

miR-181a-2-3p Stimulates Gastric Cancer Progression via Targeting MYLK

MiRNA-219a-1-3p inhibits the malignant progression of gastric cancer and is regulated by DNA methylation

MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway

miR-613 inhibits Warburg effect in gastric cancer by targeting PFKFB2

Long non-coding RNA BX357664 inhibits gastric cancer progression by sponging miR-183a-3p to regulate the PTEN expression and PI3K/AKT pathway

MiR-181d Inhibits Cell Proliferation and Metastasis Through PI3K/AKT Pathway in Gastric Cancer.

Dysregulation of NCAPG, KNL1, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer

MicroRNA-135b/CAMK2D Axis Contribute to Malignant Progression of Gastric Cancer through EMT Process Remodeling

MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression

The ELF3-regulated lncRNA UBE2CP3 is over-stabilized by RNA–RNA interactions and drives gastric cancer metastasis via miR-138-5p/ITGA2 axis

miR-133b Suppresses Invasion and Migration of Gastric Cancer Cells via the COL1A1/TGF-β Axis

MiR-378a-3p acts as a tumor suppressor in gastric cancer via directly targeting RAB31 and inhibiting the Hedgehog pathway proteins GLI1/2

miR-335-5p suppresses gastric cancer progression by targeting MAPK10